|This Energy Gradient explains the exceptional specificity of BT in fulminating conditions: in effect, the blood cells emitting biophotons are channeled as energy directly toward the fulmination, where the concentrated energy destroys the activated immune cells (or, in the case of necrotizing pancreatitis, the activated enzymes) that are driving it. In these circumstances, even amounts of BT well over the normal dosage tend to do little or no peripheral damage, in contrast to treatment with various chemotherapies.
Another possible explanation of the effectiveness of BT in the special case of liver diseases is that the blood-filtering action of the liver tends to concentrate the secondary emissions to far higher level than the modest levels in the circulating blood. This effect would suggest that BT might be equally effective in the treatment of Idiopathic Thrombocytopenic Purpura (ITP), an autoimmune disease of the spleen, another blood-filtering organ.
As a fluid the blood is capable of delivering the secondary biophotons emitted during BT process, to hard-to-get-at locations in the body which other kinds of radiation cannot reach without damaging tissue. The result is higher specificity. This would explain the action of BT in neurological disorders such as petit mal seizures. A highly successful LUBI treatment of schizophrenics with depressive syndrome resistant to all drugs (dramatic improvement in 8 out of 8 cases) resulted from the ability of the treated blood to destroy metabolically active white blood cells blocking microcirculation in the brain, for instance (Stulin et a1. (1994)). In turn, this action suggests a possible role for BT in the treatment of major depression as a substitute for Electroconvulsive Therapy. BT can be seen as a kind of glucose and ATP antagonist/substitute/over-rider and thus as a suppressor of any excessive metabolic activity in the brain or for that matter anywhere else in the body.
In contrast, in the lower concentrations with which Biophotonic Therapy affects cells;' enzymes and other factors that are under performing in certain disease states, e.g., fibrinolytic elements in arteriosclerosis BT has a stimulating effect. Thus its overall action is to normalize the situation by suppressing excessively active factors and stimulating under performers. A single dose of BT can therefore be both "immunostimulatory" and "immunosuppressive"depending on which sets of cells are under discussion. Likewise, an initial dose of BT can stimulate a cell, but then repeated doses can eventually inhibit it or destroy it. Once BT inhibits or destroys cells with excessive metabolic activity, glucose that would otherwise flow to them becomes available to underactive cells, which enhances’ the normalizing effect.
In certain disease states double- and even triple-concentration effects may occur, and these can powerfully boost BT's specificity. For instance, in a case of fulminating primary biliary cirrhosis, the initially mild level of secondary emissions in the blood could be concentrated in three ways: by the filtering action of the liver, by the blood's Energy Gradient, and by the differential absorption of the biophotons by the activated T-Cells. These effects would not merely be added to each other; they would be multiplied by each other, leading to an exceptional specificity that would explain why a relatively modest amount of extracorporeal BT can have the dramatic localized effect that it does. Of course, the labyrinthine structure of the body ensures that such a concentration does not occur in a straightforward, mathematical manner; it is the tendency toward such a concentration that counts.
The literature on BT places a good deal of emphasis on the way it oxygenates and otherwise improves the characteristics of the blood (rheological characteristics, vasodilation, and improvement in peripheral circulation). This effect occurs with unusual rapidity following transfusion of treated blood and can transform severely aggregated clumps of erythrocytes and platelets into normally diffuse, free-flowing arrays within minutes. Whether this effect should be considered part of BT's mechanism of action or rather a consequence of it, it clearly is useful in the treatment of many disorders, e.g., in achieving the gratifying results reported by Russian physicians in treating cerebrovascular, heart, and lower limb circulatory disorders. BT also significantly lessens internal bleeding after operations while permitting operations on the veins of the lower extremities with a reduced danger of renewed venous thrombosis or pulmonary embolism [Brill' (1996)]. Blood oxygenation might be connected with a known side effect of BT treatment: the creation of a small amount of ozone in the blood. It is not clear whether this ozone has any beneficial or deleterious effects.
Other short-term effects include: a modification of erythrocyte membranes that releases substances into the blood that appear to stimulate further changes; structural changes in plasma proteins (ie .can be activated up to 16 times normal);' activation of complement; immediate release of free radical oxygen, followed by a rise of antiradical factors; expansion of blood volume and slight decline in hematocrit; a drop in blood pressure; degranulation of granulocytes and mast cells; short-term decline in the number of platelets and sometimes in their functioning activation of fibrinolytic factors and reduction in the activity of coagulants; and enhanced phagocytosis. In effect, the entry of the energy from BT into the blood - a dynamic, energy - bearing fluid - changes the "correlation of forces" in the body in dozens of ways that benefit the entire organism.
It is possible that the fragments of bacteria, virus, and cells that are destroyed by BT act as a kind of vaccine in the plasma, enhancing the immune response. BT also reverses the suppression of the detoxifying function of the liver.
Finally, BT may be accompanied by psychologically-induced effects akin to a placebo effect and arising from patients' perception of it as especially powerful or as more natural than chemotherapy. In a clinical trial of LUBI in rheumatoid arthritis, a control group of 18 was given an "intrusive placebo" that consisted of the daily insertion of the IV laser waveguide, except that unbeknownst to them the laser beam was not turned on. Two patients had "significant improvement" and 12 had "improvement", which equaled the effects achieved by another group that received 4-6 sessions of LUBI over the course of two weeks though it was nowhere near as good as the response of two groups that were treated daily for six days [Zvereva et a1. (1994)].